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COUNSELING FOLLOWING DIRECT TO CONSUMER GENETIC TESTING 
FOR ALZHEIMER’S DISEASE 
MELISSA THOMAS 
ABSTRACT 
Direct to consumer (DTC) personal genetic testing (PGT) is a popular choice for 
individuals in the United States who are interested in learning more about their genetic 
health risks without formally seeing a medical professional. The company 23andMe 
offers FDA-approved genetic risk tests for conditions including late-onset Alzheimer’s 
Disease (AD), Parkinson Disease, Celiac Disease, and the BRCA1/2 mutations. Although 
this company’s genetic risk testing results are accompanied by a generic information 
sheet regarding what each individual’s result means for each condition, formal genetic 
counseling is not included in the service. However, when a condition such as late-onset 
AD has both known genetic and behavioral risk factors, counseling becomes essential in 
preventing or delaying disease onset. Following a Mediterranean-style diet, regularly 
exercising, and regularly participating in cognitive activities (e.g. reading the newspaper 
or playing a musical instrument) are each thought to be protective against developing 
late-onset AD. Previous studies have shown that customers do not usually make 
significant lifestyle modifications after completing DTC PGT, though the majority of this 
literature may not be relevant to late-onset AD as it included customers of DTC PGT 
companies that no longer exist today and the genetic risk test for late-onset AD at that 
time was not yet approved by the Food and Drug Administration.  
 vi 
The proposed study is an interventional study that will compare DTC PGT 
customer exercise, diet, and cognitive activity habits before and after a personalized 
genetics counseling session. Exercise will be measured using the Godin-Leisure Time 
Exercise Questionnaire. Diet will be evaluated by a validated food frequency 
questionnaire evaluating daily servings of fruits, vegetables, and unprocessed nuts. 
Cognitive activity at the time of survey will be evaluated by a questionnaire asking for 
the frequency of various cognitive activities, such as reading newspapers, reading books, 
artistic activities, and social activities.    
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INTRODUCTION 
Background 
Since entering the mainstream market in 2006, direct to consumer (DTC) personal 
genetic testing (PGT) has evolved into an industry that offers genetic risk tests for over 
10 conditions including Parkinson Disease, BRCA1/BRCA2 mutations, and late-onset 
Alzheimer Disease (AD).1  The Food and Drug Administration (FDA) currently classifies 
DTC genetic tests as medical devices and regulates those that have moderate to high risk 
of medical implications, such as those that test for specific disease risk.2 The agency 
generally does not review DTC tests with low medical risk, such as genetic 
predispositions towards specific muscle compositions or eye colors.2 As of 2018 the FDA 
has only approved one DTC PGT company, 23andMe, to provide disease-specific testing 
services.2  
 AD is a progressive neurodegenerative disease, and is the most common cause of 
dementia.3 The Alzheimer’s Association estimated that 5.7 million Americans lived with 
Alzheimer’s dementia in 2018.3 While there is an early-onset variation of the disease, the 
majority of Americans acquire late-onset AD.4 The cause of early-onset AD is well 
established as a single-gene mutation that can occur on one of three chromosomes, 
however, the causes of late-onset AD are not yet completely understood.4 A variant in the 
apolipoprotein E (APOE) gene is the only genetic risk factor that has been identified for 
developing late-onset AD.4 Testing for this variant is offered by 23andMe as part of their 
“Health and Ancestry” package.5 Along with genetic risk, it is thought that environmental 
and lifestyle factors also contribute to an individual’s composite risk of developing late-
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onset AD.4 A counseling session with a genetics counselor or other medical professional 
may promote modification of these additional factors to optimize disease risk reduction. 
DTC genetic tests for health risk assessments are not considered standard of care 
and, thus, there is no required medical intermediary to assist with customer counseling.6 
Although the appealing aspects of personalized medicine and patient autonomy draw 
many customers to DTC testing, it needs to be balanced with patient safety.7 While some 
DTC PGT customers elect to independently discuss their results with healthcare 
professionals, including genetics counselors and primary care providers, others believe 
that individuals should have the option to learn about their genetics without intervention 
by a medical professional.8  
Along with a desire to learn more about their genetic risks, DTC PGT customers 
report that one of their top motivations to pursue testing is to improve their health.9 
Despite this intention, several studies have observed that DTC genetic testing customers 
do not make any significant lifestyle modifications after receiving their results.10–12 
Others have shown only small behavioral changes after completing DTC PGT.13–15 It 
remains unclear whether those customers who do seek out counseling from healthcare 
professionals make more significant changes than those customers who do not.  
Statement of the problem 
Although various studies have been performed prior to 2017 on lifestyle 
modifications in customers after completing DTC PGT, the DTC market is continuously 
changing and, thus, it is an area of research that deserves further attention.10–15 The 
genetic test for late-onset AD offered by 23andMe is FDA-approved. This may have a 
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greater impact on patients than those results from DTC testing offered in the past, which 
were not approved by any government agency.6 A high genetic risk result for developing 
late-onset AD is a life changing piece of knowledge for consumers and a formal 
counseling session may assist with the implementation of healthy behavioral changes. 
The symptoms of late-onset AD have been shown to be less severe with an integrated 
intervention including a combined diet, exercise, and cognitive training program prior to 
the onset of dementia.16 Although 23andMe provides a list of local genetic counselors to 
its customers along with their disease risk results, the service does not include genetic 
counseling.17 While their service also provides a detailed guideline for how to interpret 
results and how to follow up with a medical professional, an included counseling session 
may be beneficial for patients.5   
Hypothesis 
Individuals who have completed DTC genetic testing for AD will make significant 
lifestyle changes after meeting with a genetics counselor to discuss their genetic risk 
results.  
Objective and specific aims 
As consumers continue to value personalized medicine and patient autonomy, DTC PGT 
will remain an appealing option for many individuals. This study will evaluate the 
potential benefits of receiving post-PGT counseling from a healthcare professional 
regarding patient risk for late-onset AD. The study’s specific aims are to: 
1. Compare differences in dietary habits before and after receiving PGT counseling.	
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2. Compare differences in exercise habits before and after receiving PGT 
counseling.	
3. Compare differences in cognitive and intellectual activities before and after 
receiving PGT counseling.	
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REVIEW OF THE LITERATURE 
Overview  
Direct to Consumer Genetic Testing 
Direct to consumer (DTC) genetic testing services provide customers with genetic 
analyses belonging to one of three subgroups: identity-seeking testing (ancestry or 
ethnicity testing); disease risk testing; and curiosity driven testing for specific physical 
characteristics, such as earlobe type and muscle composition.18 Customers ship a 
company providing testing services a sample of their DNA, typically saliva or a swab 
from the inside of the cheek, and avoid the process of scheduling an office visit to see a 
medical professional. Thus, DTC genetic testing is an appealing option for individuals 
who do not regularly see a healthcare provider or who have poor access to primary care 
providers or genetic specialists. Customer DNA is then analyzed for single nucleotide 
polymorphisms (SNPs), variants of single base pairs in a DNA sequence.19 For example, 
a SNP in the apolipoprotein E (APOE) gene is associated with increased risk for 
developing late-onset Alzheimer Disease (AD).5 
While DTC genetic testing is offered for multiple reasons, including learning 
more about ancestry or one’s genetics for certain traits or characteristics, the most 
controversial aspect is testing for disease-risk.18 When it was introduced, this product was 
new regulatory territory for the United States Food and Drug Administration (FDA). 
Some companies providing DTC genetic tests reported that their analyses were not 
intended to be diagnostic and, thus, should not be subject to regulation by the FDA.1 
However, the scientific and medical communities argued that customer interpretation of 
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results could have clinical implications and that the validity of these tests should be 
confirmed and monitored by a government agency.1 In 2010, these disputes led to a 
Government Accountability Office (GAO) report, as well as a congressional hearing on 
the subject of DTC genetic tests.1 The GAO report concluded that the DTC industry was 
offering misleading and impractical disease risk testing.1 While the congressional hearing 
highlighted the need for consistent, accurate DTC personal genetic testing (PGT), no 
decisions regarding regulation were made at that time.1 In 2012, the FDA determined that 
DTC genetic testing met the requirements of a device and required 23 DTC genetic 
testing companies to remove health-related interpretations from their offerings until they 
were approved the FDA.1 As a result of the new regulations, many companies stopped 
offering DTC tests. For example, Navigenics, one of the larger DTC genetic testing 
companies at the time, was sold and put an end to their health-related testing.20  
While the FDA’s 2012 decision could have permanently ended DTC disease risk 
testing, the DTC industry was optimistic in their future PGT role given continued public 
interest in genetics and precision medicine. Prior to the 2012 FDA regulations, these 
genetic tests were already in high demand - the number of companies offering DTC 
genetic testing for health-related conditions essentially doubled from 14 in 2002 to over 
30 in May 2010.21 In 2010, DTC PGT companies offered tests related to more than 50 
conditions.21 Consumer interest in these tests continued to grow and according to a 2016 
review of the industry, by January 2016 there were 246 companies offering some 
variation of web-based genetic testing.22 However, because of the 2012 FDA regulations, 
many of these companies could not offer diagnostic health-related information and 
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instead offered raw genetic testing results.22 In 2015, the web-based genetic testing 
service 23andMe adapted their testing to meet the new FDA regulations  implemented 
after the agency’s decision to increase DTC genetic testing oversight.13 In April 2017, the 
government agency approved 23andMe to provide testing for 10 additional diseases and 
conditions, including Parkinson’s disease, late onset Alzheimer’s disease, and Celiac 
disease.6 In November of that year, the FDA announced that genetic carrier screening 
tests were to be exempted from premarket review and would only be held to a one-time 
review by the FDA prior to entering the market without further view.23 This decision 
made the process for FDA approval of DTC testing significantly more streamlined and 
efficient. Most recently, in March 2018 the FDA approved 23andMe to provide 
information on 3 genetic variants of the BRCA-1 and BRCA-2 genes.24  
The demand for DTC genetic testing will continue to rise. According to a recent 
Kalorama Information report, the DTC genetic testing market was valued at around $99 
million in 2017 with a projected growth of up to $310 million by 2022.25 Contributing to 
this market growth was the 2018 announcement that the biotechnology company Perkin-
Elmer will begin to offer genetic testing for 34 conditions as a collaboration with the 
DTC sequencing group Helix.17 This projected growth, along with the 2017 FDA 
announcement introducing a more flexible approach to regulating health-related DTC 
genetic testing, suggests that personal genetic testing will continue to have a role in the 
future of health care and patient education as long as the services are affordable.23 With 
advances in genome sequencing technology, such as high-throughput sequencing, 
generating the an individual’s sequence of SNPs has become much faster and less cost 
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prohibitive.26 The cost for the health and ancestry report offered by 23andMe was $199 in 
2018, much lower than the original price of $999 in 2007.9  
Many DTC genetic testing companies only provide customers with their raw 
genetic data because they have not been approved by the FDA to offer diagnostic genetic 
tests.19 These companies typically provide customers with all of the SNPs found in their 
genotyping data, including those that are usually classified as only incidental or 
secondary findings in formal genetic testing.19 Individuals can then obtain health-related 
information from the raw genetic data by purchasing analysis through third-party 
companies, which provide more information on those genetic variants that may influence 
a customer’s medical decisions.19 In this third-party arrangement, the DTC company 
providing genetic information avoids making any health-related diagnoses or 
recommendations and typically provides a disclaimer that the information provided is not 
verified for medical use.19 Some consider this to be a loophole around FDA regulations 
on DTC genetic testing.27 Additionally, the accuracy of these third-party interpretations 
has recently been called into question. A 2017 study by Tandy-Connor et al. showed that 
a group of these third-party companies base their reports on publicly accessible genetic 
databases, which may have incorrect risk classifications.19 In general, the companies 
attempt to avoid inaccurate results by reporting on individual genetic variants, which 
reduces the use of extensive, and potentially invalidated, algorithms that simultaneously 
evaluate multiple variants for genetic risk.27   
While DTC PGT is now a regulated and FDA-approved option for patients 
interested in learning more about their genetic disease risks, the role of medical providers 
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and the level of medical guidance that should be required with DTC genetic testing 
remains controversial. Because DTC genetic tests are not considered standard of care, 
there is no required medical intermediary to assist with customer counseling after 
receiving DTC test results.6 Because each individual’s baseline knowledge of genetics 
and expectations for emotional or medical support differs, it is unclear if there should be 
an absolute requirement for DTC PGT companies to include counseling in their 
services.21 While some consumers feel that they should share their results with either 
their primary care provider or a genetics counselor, many Americans do not have 
financial or physical access to a genetics counselor and not all primary care providers feel 
comfortable interpreting the results of these DTC genetic tests.6 A 2013 study revealed 
that only 10% of physicians surveyed by the American Medical Association felt 
adequately prepared to implement genetics into their practice.28 Additionally, there are 
currently only about 4,600 genetics counselors in the United States, or about 1.4 genetics 
counselors for every 100,000 individuals.29,30 Most genetics counselors are concentrated 
in large cities with some states having only two or fewer of these professioanls.21 
Additionally, there are an estimated two to three jobs available for every graduate of a 
genetics counselor training program.17 An additional barrier to genetic counseling for 
some individuals completing DTC genetic testing is the out-of-pocket fee for a genetics 
consultation.17 Of note, 23andMe provides a list of genetics counselors in the customer’s 
area as part of their health report to facilitate a more seamless transition from the 
company to a healthcare professional, if needed.17 They do not, however, provide any 
sort of genetics counseling consultation as part of their health-related testing package.17 
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Genetics counselors also face challenges in the setting of providing counseling for 
DTC testing results. The services offered by DTC genetic companies are often composed 
of different analyses than those that would be provided by a genetics counselor.6 Also, 
when customers receive an entire risk profile based on their genetics, they may 
overwhelm a genetics counselor with concerns and questions that require more time to 
review than the allotted time for a typical general genetics consultation.21 Despite these 
challenges, the National Society of Genetic Counselors advocates for genetic counselors 
to be involved in the care of patients who have pursued DTC genetic testing and supports 
the right of individuals to pursue this testing if it is a well-informed and autonomous 
choice.6 The role of genetics counselors in addressing patient misconceptions about the 
validity and utility of testing, as well as providing patient reassurance, must continue to 
develop along with the DTC genetic testing market.6 
Genetics counselors and other medical professionals may also face difficulty 
when analyzing results with their patients because of the limitations of DTC genetic 
testing.19 Many SNP variants reported by DTC genetic testing companies are not 
absolutely causal of conditions because there are additional underlying risk factors that 
contribute to disease risk, such as an individual’s environment and lifestyle choices.19 
Patients may not understand the impact of these environmental factors when initially 
reviewing their results.19 Another limitation of DTC reports is that they may not include 
testing for all genes that are known to be associated with a specific condition. For 
example, the genetic health risk report offered by 23andMe provides the consumer’s data 
for just two variants of two genes (LRRK2, GBA) linked to Parkinson disease, while 
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there are other known pathogenic variants of those two genes, as well as other genes 
clinically linked with Parkinson disease (PARK2, PARKIN).31  
Other concerns have been raised about DTC genetic testing services, including an 
increase in patient anxiety and distress after receiving results that are not delivered in 
person and the possibility that consumers may not accurately interpret the results.32 For 
example, if a customer receives a negative result for the BRCA1/BRCA2 gene, they 
could incorrectly assume that they have no risk of developing breast cancer. While a 
potential benefit of PGT is reduced healthcare costs due to lower rates of preventable 
diseases, healthcare spending may actually rise as a result of unnecessary screening or 
diagnostic tests ordered to alleviate patient concerns.11 Additionally, because DTC PGT 
typically involves different tests than those offered by genetics counselors, excessive 
spending may also be used on in-laboratory genetic testing to confirm clinically invalid 
DTC results.19 A 2017 study by Tandy-Connor et al. found a 40% false positive rate in 
genetic variants detected by third-party DTC genetic testing.19 
The demographics of those who utilize DTC genetic testing to assess health risks 
is skewed towards wealthy white men and women and, thus, not representative of the 
wider population.10 According to a survey of 23andMe customers, most participants 
reported an annual household income of $100,000 or more.33 From this same survey, it 
was found that 80% of participants had majority European ancestry compared to around 
5% who had African ancestry.33 Similar demographics have been identified in other 
studies of DTC genetic testing customers, although the underlying reason is unclear.10 
The discrepancy in the demographics between DTC genetic testing customers and the 
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general population may contribute to socio-economic health differences.7 If, over time, 
DTC PGT is shown to significantly improve customer health, it may become an ethical 
concern that only a limited proportion of the United States population has financial 
access to these services. As the market for DTC genetic testing continues to develop, 
potential shifts in its consumer demographics will likely be monitored closely.  
Although DTC PGT has limitations, this form of genetic testing has largely been 
supported by the public’s interest in precision, genetics-based medicine and patient 
autonomy.9,7 Some patients opt for DTC PGT because they prefer a completely remote 
process in which they can independently review their results without seeing a 
professional.34 Most consumers provided the following as their reasons for purchasing 
DTC genetic health-risk tests: curiosity about their genes; a desire to find out about their 
disease-related risks; and interest in improving their health.7 Sites like 23andMe target 
these reasons when they advertise that their service can identify lifestyle factors that may 
be associated with the greatest improvements in weight based on an individual’s 
genetics.5 This potential improvement in health behaviors after utilizing DTC genetic 
testing may reduce healthcare costs associated with preventable diseases.9 
Late-onset Alzheimer Disease 
Alzheimer Disease (AD) is the most common form of dementia in the United States, with 
an estimated 5.5 million Americans affected by the late-onset form of the disease and 
around 200,000 Americans under the age of 65 living with early-onset AD.3 
Approximately two-thirds of Americans with late-onset AD are women.3 This 
discrepancy in the sex-specific prevalence of the disease is thought to be related to 
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women having longer life expectancies.3 There are also racial differences in the 
prevalence of late-onset AD, with older African Americans and Hispanics more likely 
than older Caucasians to have AD or other dementias.3 These differences are thought to 
be due to cardiovascular risk factors, including diabetes and hypertension, as opposed to 
a difference in the prevalence of high-risk genetic variants, suggesting that health 
behavior interventions may have a greater benefit on these minority populations.3  
The APOE gene is used to assess genetic risk for developing late-onset AD. The 
APOE gene is found on chromosome 19 and has three forms – e2, e3, and e4, with e3 
being the most common (Table 1).3 One copy of APOE, an allele, is inherited from each 
parent.  The presence of one copy of the e4 form of APOE increases one’s risk of 
developing late-onset AD three-fold when compared to having two e3 alleles. Those who 
inherit two copies of e4 have an eight-twelve times higher risk of developing late-onset 
AD than those with two copies of e3. The e2 allele is the least common form of APOE 
and is thought to be protective against developing late-onset AD.3  
Table 1: Estimated proportion of the United States population with the possible e2, 
e3, and e4 pairs of the Apolipoprotein E (APOE) gene. A.3 
APOE allele pair Percentage of U.S. Population 
e3/e3 61 
e3/e4 23 
e3/e/2 11 
e4/e4 2 
e2/e2 0.5 
 
In addition to genetic risk factors for late-onset AD, researchers believe that an 
individual’s risk for developing the disease is influenced by lifestyle and environment.4 
For example, the 2013 PREDIMED-NAVARRA randomized trial showed that adherence 
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to a Mediterranean-style diet with an emphasis on fruit, vegetable, and unprocessed nut 
intake improved global cognitive performance independent of APOE genotype.35 When 
educating participants on a Mediterranean-style diet, dieticians recommended cooking 
with extra-virgin olive oil, as well as consuming one ounce of unprocessed nuts and 6 
servings each of fruits and vegetables daily. Additionally, lower Mediterranean-style diet 
adherence has been associated with progressive AD biomarker abnormalities, such as 
brain beta-amyloid load, in middle-aged adults.36 Higher diet adherence was estimated to 
provide 1.5-3.5 years of protection against those abnormalities.36 Participating in physical 
activity has also been associated with a reduced risk of developing AD.37 Higher levels of 
intellectual and cognitive activities, including reading newspapers, participating in crafts 
or social activities, and playing a musical instrument, have also been associated with 
lower beta-amyloid deposition, specifically in APOE e4 carriers.38 In the setting of 
research that has shown environmental and lifestyle factors contributing towards the risk 
of developing late-onset AD, the National Institute of Health currently recommends 
against genetic testing for APOE variants in individuals as a diagnostic tool.4 In a formal 
clinical setting, APOE variant testing is typically only performed for research purposes.4 
 
Synthesis of existing research 
There is limited existing research on behavioral changes specifically after completing 
genetic testing for late-onset Alzheimer Disease (AD). Most relevant data is through 
DTC testing, not formal laboratory testing, since the National Institute of Health does not 
recommend using apolipoprotein E (APOE) variant genetic testing as a diagnostic tool 
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for AD.4 While some studies regarding DTC PGT included genetic risk testing for late-
onset AD, at the time that the studies were completed the available tests were not 
approved by the Food and Drug Administration (FDA).10,11,15 They also included 
customers who had purchased PGT from Navigenics, a company that no longer exists 
today and tested for variants of the APOC1 gene in their disease risk testing for late-onset 
AD.39 The APOC1 gene sits next to APOE on chromosome 19 but is not a perfect 
predictor of APOE genotype.39  
 A 2010 study by Vernarelli et al. examined the effect of receiving APOE 
genotype results on dietary supplement use among individuals with first-degree relatives 
with AD.40 All participants had intact cognitive function at baseline. Six weeks after 
completing late-onset AD risk assessment, 16% of the participants (N=272) reported a 
change in their use of dietary supplements. Those who had at least one copy of the risk-
increasing e4 allele were 4.75 times more likely to report a change than those who did not 
have an e4 copy (p < 0.0001).40 One limitation of the study was that patients did not 
report the exact quantities or ingredients of the supplements they were taking. Also, 
because the study only included individuals with a first-degree relative with AD, 
participant behavior at baseline may have been influenced by this increased risk 
compared to the general population.40 This study did not evaluate for health behavior 
changes in the setting of receiving genetics counseling services after completing DTC 
PGT.  
There have been prior studies on direct to consumer (DTC) personal genetic 
testing (PGT) and subsequent behavioral modifications, however, none were specific to 
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late-onset AD testing. While early proponents of DTC genetic testing suggested that its 
introduction may stimulate patient motivation to make healthier lifestyle interventions, 
several studies have shown that patient lifestyle behaviors do not necessarily change after 
completing testing.10–12 In 2011, Bloss et al. gathered information regarding patient 
exercise behavior, intake of dietary fat, and test-related anxiety both before and after they 
received results of DTC PGT. DTC genetic risk testing was completed through 
Navigenics Health Compass. Of the 3639 patients enrolled, analysis was completed on 
2037 individuals who completed follow-up surveys (mean follow-up 5.6 ±2.4 months 
after testing).10 Participants received estimated lifetime risk results for 22 conditions, 
including Graves’ disease, rheumatoid arthritis, and atrial fibrillation, with sex-specific 
calculated risks for breast and prostate cancers. In pre-testing and follow-up surveys, 
dietary fat intake was measured with the use of the 17-item Block Dietary Fat Screener. 
This screener asks about the intake frequency, from a minimum of once or less per month 
to a maximum of 5 or more times a week, of the 17 top sources of fat in the American 
diet. Exercise was assessed with the Godin Leisure-Time Exercise Questionnaire. In this 
survey, subjects report the frequency and duration of mild, moderate, and strenuous 
physical activity in an average week. These values are then weighted by each intensity of 
activity’s estimated metabolic equivalent (MET) (Table 2).10 A total score of 24 MET 
hours per week or higher is consistent with an active lifestyle.10 Situational anxiety 
surrounding testing was measured with a 20-item subscale of the Spielberger State-Trait 
anxiety Inventory. At the time of follow-up, there were no significant differences 
between baseline and follow-up survey results in dietary fat intake, exercise, or anxiety.10 
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Table 2: Qualifying activities for each activity type on Godin Leisure-Time 
Exercise Questionnaire.10 
Activity Type Examples 
Strenuous exercise (9 METs; rapid 
heart beat) 
running, jogging, vigorous swimming or 
bicycling, basketball, soccer, cross country 
skiing 
Moderate exercise (5 METs; not 
exhausting) 
fast walking, tennis, badminton, easy swimming 
or bicycling, alpine skiing 
Mild exercise (3 METs; minimal 
effort) easy walking, yoga, fishing, bowling, golf 
 
Of note, a limitation of this study was its high drop-out rate. 44% of individuals 
who elected to undergo testing in the beginning were lost to follow-up.10 Although it is a 
convenient data collection method, it is also easy for participants to ignore. Another 
possible explanation for this high follow-up failure rate is that subject spouses and family 
members were also allowed to be enrolled in the study and, therefore, each failure to 
follow-up was unlikely to be independent.10 Another limitation of this study is that the 
population is not representative of the general U.S. population, although it is 
representative of those who purchase DTC genetic testing. Of those who completed the 
six month follow-up, 84.2% of the participants were white, 23.6% were employees of 
Scripps Research Institute, which partly supported the project, and 70.4% of participants 
reported an annual income greater than or equal to $100,000.10 
In 2013, Bloss et al. published results from a one year follow-up of the same 
participants of their 2011 study.10,11 A web survey was used once again and a total of 
three email requests within a 6-week time frame were sent to each individual as a 
reminder to complete the questionnaire. In those that completed the one-year follow-up 
(N=1325), there were no statistically significant differences between their baseline 
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behaviors and those one year post-PGT in regards to anxiety, dietary fat intake, or 
exercise behavior.11 The 2011 and 2013 Bloss studies found no significant diet or 
exercise changes at both the six month and one year follow-up periods, suggesting that 
DTC genetic testing may not motivate behavioral changes. These studies were 
appropriately powered with the large sample size and used validated tests including the 
17-item Block Dietary Fat Screener and the Godin Leisure-Time Exercise Questionnaire. 
The use of web-based surveys may be a source of self-report bias or selective recall. If 
this were the case, though,, falsely reported favorable lifestyle modifications after DTC 
PGT would be expected and more significant diet and exercise changes would have been 
found. It is also possible that self-reporting bias led to participants overestimating their 
baseline habits, reducing the ability to detect any significant changes to behavior.   
These studies also evaluated the relationship between the magnitude of behavioral 
changes and an individual’s average estimated lifetime risk for conditions included in the 
genetic screening using linear regression. The hypothesis was that those with high 
lifetime risk would make more significant positive lifestyle changes. However, very few 
significant associations were observed between elevated risk for a specific disease and 
change in behavior post-PGT. Those that were significant were nominally so. Using the 
Godin Leisure-Time Exercise Questionnaire, exercise scores increased long-term by 0.59 
MET hours per week in the population at elevated lifetime risk of developing atrial 
fibrillation (p=0.01) and by 0.50 MET hours per week in the population who received a 
higher than average risk result for developing atrial fibrillation (p=0.02).11 These are not 
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clinically significant changes. An increase of 0.50 MET hours only represents about 10 
minutes of light intensity exercise. 
Together, the 2011 and 2013 Bloss studies found that Navigenics Health Compass 
customers were unlikely to make lifestyle changes six months or one year after receiving 
their health-related risks scores.10,11,20 Of note, Navigencs Health Compass no longer 
exists today. Today’s major DTC genetic testing company, 23andMe, offers health risk-
related genetic tests, but not for many of the conditions (including atrial fibrillation) that 
were included in the Navigenics panel.5 While the results from these studies may not be 
directly applicable to today’s DTC market, customer reactions may be similar after 
receiving risk scores for diseases, such as AD, that may be linked to poor diet and 
exercise habits.16 
In 2017 Gray et al. studied behavior changes in customers who specifically 
underwent DTC single-nucleotide polymorphism (SNP)-based cancer risk testing.12 This 
longitudinal study analyzed baseline (pre-testing) and 6-month response surveys from 
762 customers of 23andMe and Pathway Genomics. The 6 month survey asked 
participants if they had made changes in their diet, exercise behavior, advanced care 
planning behavior, or use of vitamins/herbal supplements in response to their PGT 
results.41 Of note, none of the customers tested positive for genetic variants that are very 
strongly associated with a malignant diagnosis, however, a minority of individuals 
received mildly elevated SNP-based PGT cancer risk estimates –24% of individuals 
received elevated SNP-based genetic risk for colorectal cancer, 24% for prostate cancer, 
and 12% for breast cancer.12 The percentage of individuals who reported making diet or 
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exercise changes after receiving their SNP-based cancer risk estimates was not 
significantly different between those with elevated risk estimates and those with 
average/reduced risk estimates for developing breast, colorectal, or prostate cancers 
(Table 3).12 The elevated risk group was also not significantly more likely to make 
changes in regards to cancer screenings, including mammography for breast cancer, 
colonoscopy for colorectal cancer, and PSA testing for prostate cancer.12 Of note, 
customers over the age of 50 were high users of cancer screening tests at baseline as most 
screening tests in the United States are recommended in patients 50 years of age and 
older. Because of this population’s high use of screening tests at baseline, this group was 
less likely to have a significant increase in the use of these measures after genetic cancer 
risk testing. This is unlikely to affect results of the study population as a whole as only 
36% of participants were over the age of 50.12 One significant finding in this study was 
that men with an elevated risk of prostate cancer were more likely to change their use of 
vitamins/herbal supplements more often than men with non-elevated risk of prostate 
cancer (25.0% vs. 11.6% of patients, p=0.008).15 However, these results may be due to an 
alpha error given the high number of comparisons made in this study. A limitation of the 
Gray et al. 2017 study included a relatively small number of customers with elevated 
cancer risk scores. Because of this there was limited power to detect small behavioral 
changes. While the initial baseline survey used by Gray et al. asked participants 
specifically about their daily consumption of fruits/vegetables and number of days per 
week they participated in vigorous, moderate, and strengthening exercises, the study does 
not specify the language used in the 6-month post-PGT survey. Based on the published 
 21 
study, the follow-up survey only asked participants if they had made any changes to their 
diet or exercise routines but did not quantify these changes, which may have provided 
more meaningful results. Also, greater changes in behavior may have been observed if 
the study included customers who had received positive results for the more highly 
penetrant genes of breast, colorectal, and prostate cancers.  
Table 3: Associations of genetic risk scores with diet and exercise modifications at 6 
month follow up.12 
PGT Cancer 
Risk 
# 
Patients 
% of 
patients who 
changed diet 
p-
value 
  
# 
Patients 
% of 
patients who 
changed 
exercise 
p-
value 
Breast CA             
Not elevated 375 34.7 
0.5 
375 27.7 
0.57 
Elevated 44 29.5 44 31.8 
Colorectal CA             
Not elevated 524 30.3 0.73 524 24.0 0.27 
Elevated 166 28.9 166 28.3 
Prostate CA             
Not elevated 207 24.2 0.70 207 18.4 0.52 
Elevated 64 26.6 64 2.7 
 
A recurring limitation in studies of DTC genetic testing is the lack of 
generalizability to the United States population as a whole.10,12 While the populations in 
these studies are representative of current DTC consumers, in most cases the baseline 
characteristics of study participants are not consistent with the national population10. In 
the 2017 study by Gray et al., the baseline participant characteristics were 21% non-white 
or Hispanic, 60% female, and 56% employed with full-time positions with 43% reporting 
a household income ³ $100,000.12 For example, the 2017 Gray et al. study noted that 
after comparing patient baseline behavioral survey results with national 
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recommendations, 43% of participants had reported dietary habits that met CDC dietary 
guidelines and 35% reported exercise routines that met CDC exercise 
recommendations.12 According to a 2017 CDC press release, only 9% of American adults 
meet recommendations for vegetable intake and 12% meet recommendations for 
adequate fruit intake.42 If these studies had included individuals with baseline health 
habits that are more similar to those of the general American population, significant post-
DTC PGT behavioral modifications may have been observed. As the market for DTC 
genetic testing evolves and the services become accessible to a wider range of 
individuals, the demographics of those who utilize DTC genetic testing, along with their 
health modifications, may change. 
Some studies have, however, found significant changes in health behaviors after 
DTC PGT.13,14 A longitudinal study by Olfson et al. (2016) specifically evaluated 
changes in smoking behaviors of 23andMe and Pathway Genomics customers after 
receiving DTC PGT (N=1002).13 The study participants at baseline included 64 current 
smokers, 270 former smokers, and 646 never smokers. At the 6-month follow up survey 
only 13 (1%) of the 916 former and never smokers started smoking, while 14 (22%) of 
the 64 current smokers at baseline reported quitting.13 This cessation rate is much higher 
than that reported by the 2000-2015 National Health Interview Survey, which found that 
only 7.4% of smokers who made a cessation effort were able to recently quit smoking.43 
Secondary analyses showed that participants who had quit smoking at 6 months did not 
tend to have significantly higher genetic risk results for lung cancer or heart disease than 
the other study participants, including those who were smokers and did not quit.13 Olfson 
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et al. also showed that current smokers at baseline were more interested in their genetic 
risk results for lung cancer than former and never smokers (OR = 1.8, p<0.0001).13 
Across the various smoking status groups, there was no difference in the level of interest 
for results regarding risk of developing heart disease.13 The limitations of this study 
include a rather homogenous population, including 90% white and 78% college 
graduates, and a small sample size of smokers at baseline. The demographics of the study 
may have contributed to the high cessation rate in participants, as smokers with a 
bachelor’s degree or higher smoke cigarettes for about half as many years as those with a 
high school level of education.41  
Nielsen et al. used a web-based survey to evaluate fruit, vegetable intake and 
frequency of various classifications of exercise both before and 6 months after receiving 
PGT results.15 The study included 1,002 customers of 23andMe and Pathway Genomics. 
This study was similar to those completed by Bloss et al., however, Nielsen et al. 
performed a secondary analysis, stratifying their results by customer baseline self-
reported health (SRH). SRH was assessed at baseline using a validated 5-point scale to 
answer questions about one’s general health, including physical activity, diet, mood, and 
energy levels.15 Among those individuals with lower baseline SRH scores there were 
significant increases in all outcomes (Table 4).15 These increases were modest with little 
clinical relevance. When the results were not stratified by baseline SRH, there were only 
significant changes in vegetable intake (p=0.0003) and strength exercise (p=0.0153).15 
These changes were again modest and likely not clinically relevant with estimated 
vegetable intake increasing by only 0.11 servings per day and reported frequency of 
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strength exercise increasing by 0.14 days per week.15 The survey also asked if diet and 
exercise changes were specifically motivated by PGT results with 30% of subjects 
reporting having made a diet change and 26% of subjects reporting having changed their 
exercise explicitly based on their PGT results.15 These rather low percentages may 
indicate that the DTC PGT customers were ready to make lifestyle modifications 
regardless of completing PGT or not. The authors of this article admitted that given the 
small magnitude of changes they observed, DTC PGT is likely very limited in its ability 
to effect change.15 Similar to others, this study introduced a potential self-reporting bias 
by using web-based surveys.  
 
Table 4: Behavioral observations of lower baseline SRH individuals 6 months after 
completing DTC genetic testing.15 
Behavior Delta p-value 
Fruit intake (servings/day) 0.11 0.0148 
Vegetable intake (servings/day) 0.16 0.0005 
Light exercise (days/week) 0.25 0.0263 
Vigorous exercise (days/week) 0.23 0.0097 
Strength exercise (days/week) 0.19 0.0369 
 
In 2018, Hayashi et al. studied lifestyle interventions, including changes in diet, 
exercise, alcohol use, and smoking habits after participants received results of personal 
genetic testing.14 Of note, in this study the testing was not DTC but rather completed at a 
heredity clinic at the University of Tokyo Institute of Medical Science. Participants met 
one-on-one with physicians at the time of study consent and also received about one hour 
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of counseling from the same physician at the time of their genetic risk result disclosure. 
Patient behavior was evaluated pre-PGT and 3, 6, and 12 months post-PGT. While Bloss 
et al. used specific questions, including the Block Dietary Fat Screener and a detailed 
exercise log in their follow-up questionnaires, the questions used by Hayashi et al. were 
much more general with the option to provide additional details in a free response 
section.10,14 The follow-up questionnaires asked participants if they changed their diet, 
exercise routine, tobacco use, or alcohol use, but did not quantify these changes.14 
Among the 20 subjects, over 60% changed their lifestyles in favor of disease 
prevention.14 There were significant increases between the pre and post-PGT scores for 
patient awareness of ability to prevent disease with lifestyle changes and understanding 
of the diseases that they might suffer from in the future (Table 5).14   
Table 5: Mean scores of perceived levels of health and future disease risk prior to 
and after PGT.14 *Scores range on a scale of 0-10. 
Survey Question 
Mean 
score 
pre-
PGT* 
Mean 
score post-
PGT* 
p value 
If you become sick in 10 years' time, 
how well do you think you could 
control your illness? 
5.75 7.1 < 0.01 
How well does your lifestyle and life 
attitude help prevention of the diseases 
you might get in 10 years' time? 
4.75 6.4 < 0.05 
How well do you think you understand 
the disease you might suffer from in the 
future? 
5.65 8.1 < 0.01 
 
Although the 2018 Hayashi et al. study used subjects who sought genetic testing 
through a medical office instead of a DTC service, the results suggest that combining 
PGT with a medical professional consultation may be effective at motivating healthy 
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lifestyle modifications. While physicians provided the counseling in this study, a 
consultation with a genetics counselor in the United States would likely cover the same 
topics and have similar effects. Limitations of this study included a small sample size 
(n=20) that is not generalizable to the U.S. population as all 20 subjects were Asian and 
live in Japan. Another limitation in this study is that the phrasing of the questionnaire 
may have led to a greater self-reporting bias than the Bloss et al. 2011, 2013 studies. It 
would be much easier for a study subject to claim they had made a positive change to 
their diet than to systematically do so in the 17-item Block Dietary Fat Screener used in 
the Bloss et al. studies to evaluate dietary changes.10,11 Although significant changes in 
positive lifestyle behaviors were found by Hayashi et al., it is unclear if the model they 
used can be realistically reproduced. While private companies offering health-related 
genetic testing could reasonably offer online consultations, it is unlikely that they would 
be able to provide the one hour medical consultation included in the study protocol by 
Hayashi et al.14 
Although most studies in this area of research have found that DTC PGT 
customers do not make clinically significant changes to their diet or exercise routines 
after completing disease risk testing, there is no existing research on the most recent, 
FDA-approved DTC testing for late-onset AD. Because there are lifestyle-associated risk 
factors for developing late-onset AD, a genetics counseling session to address lifestyle 
modifications after receiving DTC disease risk results would likely be beneficial for DTC 
PGT customers.  
  
 27 
METHODS 
Study design 
The proposed study will be a before-after interventional study evaluating dietary habits 
and physical activity of direct to consumer (DTC) personal genetic testing (PGT) 
customers at baseline prior to receiving PGT results, 2 weeks after receiving results pre-
genetic counseling, 4 weeks after receiving results post-genetic counseling, and 6 months 
after receiving results post-genetic counseling. Ongoing cognitive activity will also be 
evaluated in the study population at baseline, as well as before and after genetic 
counseling. 
Study population and sampling 
The study population will consist of adults who purchased the DTC 23andMe genetic 
health risk testing service, which includes testing for late-onset Alzheimer Disease (AD). 
All subjects will be 18 years of age or older. The sample size will need to be 
approximately 142 individuals to detect a significant difference in physical activity after 
receiving genetic counseling, calculated in metabolic equivalents (METs) per week. The 
sample size was calculated based on the results of Bloss et al. (2013) using an alpha of 
0.05, estimated power of 80%, an effect size of 5, and a standard deviation of 21.270.11,44 
While the effect size found by Bloss et al. in 2013 was 1.9 metabolic equivalent (MET) 
hours per week, five was selected for this study as it represents the addition of one hour 
of moderate exercise, or approximately 2 hours of light exercise, in a week.10 This sample 
size will also be adequately powered to detect a significant difference in the number of 
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daily servings of fruit, vegetables, and unprocessed nuts using an alpha of 0.05, estimated 
power of 80%, an effect size of 0.5, and standard deviation of 1.1.15,44  
Intervention 
All participants in the study will be offered free-of-charge genetic counseling after 
receiving the results of their DTC health risk testing. Each genetics counseling session 
will last approximately 20 minutes and will review each participant’s late-onset AD 
genetic testing results. Lifestyle modification strategies to reduce risk will be reviewed in 
detail during these sessions. Of note, all individuals, including those who decline genetic 
counseling, receive an information sheet from 23andMe that includes recommendations 
regarding diet, heart health, and intellectual activity.5 Counseling sessions may either be 
held in person or remotely via Thera-link, a secure, HIPAA-compliant web-based 
conference system. Participants will be able to choose between these two options based 
on their location and the feasibility of scheduling an in-person counseling session.  
Project variables and measurement tools 
Demographics 
Participants will complete a demographics survey prior to receiving their genetic results. 
This survey will gather information on sex (male, female, other), age, income, education 
level (some high school, high school degree, four-year college degree, post-graduate 
degree), occupation, and race (White, Black, Hispanic, other).  
Physical Activity 
The Godin Leisure-Time Exercise Questionnaire, used by Bloss et al. (2011, 2013) will 
be used to evaluate differences in physical activity between baseline, pre-genetic 
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counseling, and post-genetic counseling time points. The questionnaire will gather 
information on the frequency and duration of strenuous, moderate, and mild exercise per 
week. The frequency of exercise sessions per week within each category of intensity will 
be multiplied by the average reported duration, weighted by its respective MET (3 METs 
for light exercise, 5 for moderate exercise, and 9 for strenuous exercise).10 Then, all 
intensities will be summed to produce a value expressed in average MET hours per 
week.10 In this questionnaire, scores are calculated as a weekly leisure activity score, and 
may range from 0 to 246. This questionnaire has a test re-test reliability of 0.62.10  
Diet 
Because of the association between following a Mediterranean-style diet and a reduced 
risk of developing AD, the study’s questionnaire regarding diet habits will focus on 
Mediterranean-style diet recommendations. A food frequency questionnaire utilized by 
Nielsen et al. will be used to assess average daily servings of fruits, vegetables, and 
unprocessed nuts, with the following possible frequency responses: None; £1; 2; 3; 4; 5; 
³6.15 The survey will define what constitutes a serving of each of these categories. 
Cognitive Activities  
Cognitive training behavior will be measured through a questionnaire of patient reported 
frequency of participating in the following activities: reading newspapers, reading 
magazines, reading books, playing games, playing musical instruments, artistic activities, 
craft activities, group activities, social activities, and computer activities. Patients will 
report how many times they participate in each activity in an average week.38 The scores 
for each activity will be added into one total cognitive activity score for each participant.  
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Recruitment 
Recruitment for this study will be modeled after the Impact of Personal Genomics Study, 
which began recruitment in March of 2012.45 Participants for the study will be recruited 
with the assistance of the DTC PGT company 23andMe. Customers who purchase 
genetic health risk testing and provide informed consent to participate in research will be 
contacted directly by 23andMe with an email outlining the proposed study and inviting 
them to participate. As part of the study consent process, subjects will agree to share their 
genetic risk information with the study team. Each participant will be identified by a 
unique survey ID that will be linked to their genetic risk information to maintain subject 
confidentiality.45 Due to an expected 40% loss to follow-up rate based on past studies, 
recruiting will end after 250 participants have confirmed that they have completed the 
genetics counseling session.10 Prior to that time, patients will be recruited continuously. 
Data collection 
Data will be collected using Qualtrics, a web-based survey service. Participants will also 
use this service to provide the study team with the date of their genetic counseling session 
after completion. Because all participants were able to purchase DTC PGT online, they 
should have adequate access to web-based surveys.  
Data analysis 
Percentages of the study population who are male, female, White, Black/African 
American, Hispanic, and other races will be calculated. Percentages of the highest level 
of education, including some high school education, high school degree, four-year 
college degree, and post-graduate degree, will be calculated in the study population. 
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Average age and income of all participants will be calculated. Exercise, diet, and 
cognitive activity data from pre- and post-genetic counseling will be analyzed with paired 
t-tests analyzing the mean change and standard deviation among the survey variables. 
Patient-reported behavioral baseline data and pre-genetic counseling data will also be 
compared with paired t-tests to analyze for any changes in behavior that may be due to 
results provided by 23andMe prior to intervention. For diet, separate analysis by means 
of the Wilcoxon signed-rank test will be performed on fruit, vegetable, and unprocessed 
nut intake. Because multiple comparisons will be made regarding diet changes, there is 
an increased possibility for committing an alpha error in at least one pairwise 
comparison. The Bonferroni correction method will be used to control for this potential 
error.46 The average changes in reported exercise, diet, and cognitive activity in those 
who complete in-person genetic counseling will be compared with those who complete 
remote genetic counseling using an unpaired t-test. Also, to evaluate for differences in 
behavioral change based on genetic risk, exercise, diet, and cognitive activity changes 
between those with elevated genetic risk for late-onset AD and those with normal genetic 
risk will be compared using linear regression.   
Timeline and resources 
Six months prior to initiation of recruitment, study investigators will begin to meet and 
collaborate with representatives from 23andMe. Ethics, the informed consent process, 
and de-identifying of patient information will be discussed. Recruitment of genetics 
counselors who will provide counseling sessions will begin 4 months prior to subject 
recruitment. This is adequate time to recruit genetics counselors and establish their access 
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to Thera-link for remote counseling sessions. The Principal Investigator will be a 
certified genetics counselor and co-investigators will include physicians, physician 
assistants, and additional genetics counselors. One month prior to recruitment, the study 
will be submitted to the Boston University Medical Campus Institutional Review Board. 
While the average number of new 23andMe genetic health risk customers per 
month is unknown, patient recruitment will be expected to be completed four to six 
months after its initiation.45 Administrative support in the form of four student workers or 
research assistants will be required to assist in data entry.   
Data analysis will be completed one year after initiation of recruitment. At this 
time, six-month post-genetic counseling data for all participants will have been collected 
and available for analysis. A statistician will be consulted at this time. A manuscript will 
be submitted when data analysis is complete. 
The study team will apply for funding from the National Institute of Health and 
the National Human Genome Research Institute to compensate genetics counselors for 
their services. 
Institutional Review Board 
The study investigates individual behavior and proposes no significant harm to 
participants and, thus, under common rule expedited category number seven, will be 
submitted to the Boston University Medical Campus Institutional Review Board for 
expedited review.47 
  
 33 
CONCLUSION 
Discussion  
This study will evaluate the role of genetics counselors in promoting beneficial lifestyle 
modifications in direct to consumer (DTC) personal genetic testing (PGT) customers 
after receiving genetic risk assessment for late-onset Alzheimer Disease (AD). Customer 
behavior will be assessed at baseline, 2 weeks after receiving DTC genetic testing results 
pre-counseling, 4 weeks after receiving genetic counseling, and 6 months after receiving 
genetic counseling. Although DTC genetic risk testing may reveal significant disease 
risk, genetics counseling sessions or referrals are not currently required to accompany 
this form of testing. For diseases that can be affected by behavioral factors as well as 
genetic risk factors, a detailed counseling session may be beneficial for DTC genetic risk 
testing customers. The study is unique because it will compare behavior of individuals 
before and after receiving post-DTC genetics counseling, instead of comparing 
individuals before and after completing DTC testing. The study is designed as such to 
reduce the bias that would be present between individuals who chose to complete genetic 
counseling, who likely have more resources and motivation to change their behavior, and 
those who do not. Also, unlike previous studies, this proposal will provide free genetic 
counseling, either in-person or remotely, to any participants who are interested. This will 
remove the financial and accessibility burden of genetics counseling on participants. It 
has been shown that up to 38% of DTC PGT customers who did not utilize in-person 
genetic counseling would have done so if it had been made available to them.1 The study 
is also unique in that it will analyze cognitive activities.  
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This study has several limitations. First, using patient reported data from web-
based surveys could introduce a potential self-reporting bias. Participants may 
overestimate healthy changes in their lifestyle choices if they suspect that they are 
expected to be making these changes. There is also expected to be a degree of recall bias 
when participants estimate their behaviors in an average week. There will be selection 
bias as the individuals who agree to the free genetics counseling session are more likely 
to be motivated to improve their health behaviors than those who decline the genetics 
counseling service. The individuals who participate in this study are also more likely to 
be motivated to make behavioral changes than the general population because they chose 
to purchase DTC disease risk testing, demonstrating an interest in their health. There is 
also potential that an individual’s knowledge of their personal risk for other diseases, 
including coronary artery disease or certain malignancies, may influence their behavioral 
changes and therefore influence study results. This would be addressed by further 
analysis of personal health risk knowledge before genetic testing.  
There is also inherent limitation in this study because there is no way to prove that 
a participant’s behavioral changes are directly related to the genetics counseling that they 
receive. The survey 6 months after counseling will have limitations of its own as fewer 
subjects are likely to respond to this long-term follow-up. Another limitation of the study 
is that while genetics counselors receive similar training and will be instructed to review 
specific recommendations, their discussions with study participants cannot be completely 
standardized. Additionally, there may be differences observed in the behavioral changes 
between participants who completed in-person genetics counseling and those who 
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completed remote counseling. The benefit, however, of adding remote counseling as an 
option for those who do not have geographic access to a counselor is important for 
recruitment purposes.  
Similar to the existing literature, the participants in this study may not be 
generalizable to the United States population because wealthy white men and women 
have been found to purchase DTC PGT more frequently than other demographics.10,33 
However, the study will be representative of the general population who undergoes DTC 
PGT. Of note, the demographics in this study may be more diverse than in studies in the 
past because DTC is now more established, widespread, and potentially more affordable 
for a greater proportion of the population. In past DTC PGT studies, African Americans 
and Hispanics have been underrepresented. These groups, however, are more likely than 
Caucasians to have AD or other dementias.3 The racial differences in the prevalence of 
AD are thought to be due to cardiovascular risk factors, including diabetes and 
hypertension, as opposed to a difference in the prevalence of high-risk apolipoprotein E 
(APOE) gene variants.3 This suggests that lifestyle changes may have a more beneficial 
long-term effect for these patients.  
A potential obstacle for the study will be acquiring funding to appropriately 
compensate genetics counselors and the research team, including research assistants and 
statisticians. There are few obstacles expected to obtain a sample size of 250 individuals, 
as 23andMe has over 5 million customers, .17  
Summary 
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As DTC PGT continues to be an appealing option for many Americans who are interested 
in their genetic health risks, high-quality patient education and opportunity for follow-up 
will be crucial for patient safety. 23andMe already provides generalized fact sheets about 
results for their genetic risk testing but does not provide a personalized genetics 
counseling session or an automatic referral to a genetics counselor. This study hopes to 
evaluate the role of genetics counselors in behavior modifications following DTC disease 
risk testing, specifically for late-onset Alzheimer Disease (AD), a condition which is 
known to have lifestyle as well as genetic risk factors.3 This study will evaluate changes 
in exercise, diet, and cognitive activity that are protective against developing AD before 
and after receiving genetic counseling.  
Public health significance 
A potential implication of this study is a change in regulating DTC genetic risk testing. 
The DTC genetic risk testing industry has evolved from a completely unregulated field to 
one that was almost ended by the Food and Drug Administration (FDA) in 2012 to an 
industry in which 23andMe can offer multiple FDA-approved genetic risk tests including 
one for late-onset (AD).1,19 The DTC PGT market continues to grow and in 2018 DTC 
disease risk testing began to be offered by a collaboration between Perkin-Elmer and 
Helix.17 However, if this study suggests that genetics counseling improves health 
behavior in DTC customers, the FDA may decide to make stronger recommendations for 
DTC customers to seek out genetic counseling services. The FDA will not be able to 
mandate that individuals receive genetic counseling, but it can publish guidelines for the 
American public regarding what they should do with their results. Alternatively, they 
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may make stronger recommendations that individuals seek out genetic testing in a formal, 
laboratory setting with a healthcare professional instead of pursuing DTC options.  
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